Rechavia E, Litvack F, Macko G, Eigler N L
Department of Medicine, University of California-Los Angeles School of Medicine.
J Am Coll Cardiol. 1995 Mar 15;25(4):866-70. doi: 10.1016/0735-1097(94)00457-2.
This study examined the immediate angiographic and long-term clinical results of stenting saphenous vein graft aorto-ostial stenosis at a single center.
Data on the feasibility, safety and short- and long-term clinical results of stent implantation in aorto-ostial lesions in patients with unstable angina are limited.
Palmaz or Palmaz-Schatz stents were deployed in 29 patients (mean [+/- SD] age 70 +/- 10 years) with complex (B2 or C) vein graft aorto-ostial lesion morphology. All patients had angina at rest; 23 (79%) had a previous myocardial infarction; and 13 (45%) had two previous bypass operations (mean graft age 9 +/- 5 years). Mean left ventricular ejection fraction was 42 +/- 13%.
Thirty-two stents were deployed in 25 new and 4 restenotic aorto-ostial lesions. Ten additional stents were implanted in five patients for eight lesions other than at ostial locations. Stent implantation was successful in all patients. There was no death, Q wave myocardial infarction, bypass surgery or stent thrombosis in the first 30 days. Stenting improved minimal lumen diameter from 0.7 +/- 0.5 mm (95% confidence interval [CI] 0.5 to 0.8) to 3.3 +/- 0.5 mm (CI 3.2 to 3.5) and percent diameter stenosis from 80 +/- 13% (CI 75% to 85%) to 1 +/- 12% (CI -3% to 6%) (p < 0.001 for both variables). Immediate loss from recoil was 0.2 +/- 0.2 mm (CI 0.2 to 0.3), corresponding to a percent recoil of 7 +/- 5% (CI 5% to 9%). Clinical follow-up in all patients at a mean of 11 +/- 8 months revealed that 27 patients (94%) were free of death or myocardial infarction. Bypass surgery and balloon angioplasty were required in one (3%) and two (6%) patients, respectively. In 21 (88%) of the remaining 24 patients, symptoms were lessened by two or more symptom classes.
Palmaz or Palmaz-Schatz stent implantation for saphenous vein graft aorto-ostial stenosis has a high likelihood of immediate success and is associated with a large immediate gain in lumen diameter. Thirty-day and long-term adverse event rates are low. These data suggest that stenting saphenous vein graft aorto-ostial lesions is an acceptable therapeutic option in selected elderly patients with unstable angina and large-diameter vessels.
本研究在单一中心考察了对隐静脉移植血管主动脉开口处狭窄进行支架置入的即刻血管造影结果和长期临床疗效。
关于不稳定型心绞痛患者主动脉开口处病变进行支架植入的可行性、安全性以及短期和长期临床疗效的数据有限。
对29例(平均[±标准差]年龄70±10岁)具有复杂(B2或C型)静脉移植血管主动脉开口处病变形态的患者植入Palmaz或Palmaz-Schatz支架。所有患者均有静息性心绞痛;23例(79%)曾有心肌梗死;13例(45%)曾接受过两次搭桥手术(平均移植血管使用年限9±5年)。平均左心室射血分数为42±13%。
在25处新的和4处再狭窄的主动脉开口处病变中植入了32枚支架。另外在5例患者的8处非开口部位病变中植入了10枚支架。所有患者的支架植入均获成功。在最初30天内无死亡、Q波心肌梗死、搭桥手术或支架血栓形成。支架置入使最小管腔直径从0.7±0.5mm(95%可信区间[CI]0.5至0.8)增至3.3±0.5mm(CI 3.2至3.5),直径狭窄百分比从80±13%(CI 75%至85%)降至1±12%(CI -3%至6%)(两个变量p均<0.001)。因弹性回缩造成的即刻管腔丢失为0.2±0.2mm(CI 0.2至0.3),对应弹性回缩百分比为7±5%(CI 5%至9%)。对所有患者进行平均11±8个月的临床随访显示,27例(94%)患者无死亡或心肌梗死。分别有1例(3%)和2例(6%)患者需要进行搭桥手术和球囊血管成形术。在其余24例患者中的21例(88%),症状减轻了两级或更多级。
对隐静脉移植血管主动脉开口处狭窄植入Palmaz或Palmaz-Schatz支架即刻成功率高,且管腔直径有显著即刻增加。30天和长期不良事件发生率低。这些数据表明,对选定的老年不稳定型心绞痛和大直径血管患者,对隐静脉移植血管主动脉开口处病变进行支架置入是一种可接受的治疗选择。